Tofacitinib Shows Potential as Therapeutic Option for CNS Autoimmune Diseases
Future analysis evaluating the optimal candidate for disease and duration of treatment for the use of tofacitinib in autoimmune encephalitis is needed, according to the study authors.
Soon-Tae Lee, MD
Findings published from a retrospective study evaluating the off-label use of tofacitinib (Xeljanz; Pfizer) in a small cohort of patients with refractory autoimmune encephalitis suggest there may be potential for the drug as a therapeutic.1
Among a cohort of 8 patients treated with tofacitinib, 2 (25%; patients 1 and 8) had good responses, 3 (37.5%; patients 3, 5, and 6) had partial response, and the other 3 (37.5%; patients 2, 4, and 7) had no response. Good response was defined as having Clinical Global Impression score (CGI-I) of 1, whereas scores of 3 and 4 represented partial and no responses to treatment, respectively.
Senior author Soon-Tae Lee, MD, associate professor of neurology, Seoul National University Hospital, and colleagues evaluated the efficacy of 5mg tofacitinib, a Janus kinase (JAK) 1 and 3 inhibitor, administered orally twice daily in patients with refractory autoimmune encephalitis. Despite the small-numbered cohort, Jang and colleagues concluded that the data, “adds important clinical evidence suggesting the possible efficacy of JAK inhibitors in CNS autoimmune diseases.”
Tofacitinib has previously shown to penetrate the blood-brain barrier (BBB) and is effective against refractory immune-mediated diseases, such as rheumatoid arthritis, psoriasis, and ulcerative colitis. The drug received FDA approval to treat rheumatoid arthritis in 2012, and later gained approvals to treat active psoriatic arthritis, severely active ulcerative colitis, and active polyarticular course juvenile idiopathic arthritis in 2017 and 2018, respectively.2
READ MORE: FDA Clears Pediatric Version of NeuroCap EEG Headset
Jang and colleagues also found that 1 patient had complete remission of chronic meningoencephalitis, showing improved neurologic symptoms and brain lesions in magnetic resonance imaging (MRI).1
Patient 8, who presented with new-onset refractory status epilepticus (NORSE) symptoms in anti-myelin oligodendrocyte glycoprotein (MOG)-associated disorder, had electroencephalogram (EEG) features improved after treatment with tofacitinib, and by day 16, had symptoms terminated.
Among patients who reported a partial response, tofacitinib stopped the worsening in patients 3 and 5 who were in the course of disease exacerbation. Of note, severe dyskinesia was improved in patient 6.
Mild nausea and transient neutropenia without fever, each found in 1 patient, were the only adverse events (AEs) recorded in the study, both tolerable in nature. No other patients had AEs. The researchers also examined cytokine profiles in 5 patients whose samples were available but found no significant differences between the good response group and the others.
Patient 1, who was among the 2 who showed good response, showed severe cognitive dysfunction and gait instability with a Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score of 13, Mini-Mental State Examination (MMSE) score of 13, and modified Rankin Scale (mRS) score of 4 at presentation.
After 1 month of treatment with tofacitinib, the patient’s condition drastically improved. The symptoms improved to CASE score of 2 and mRS of 2 with only mild memory impairment. Brain MRI also revealed no more diffusion restriction or leptomeningeal enhancement. Kang and colleagues noted that he’s remained on treatment with tofacitinib monotherapy for 16 months without any AEs.
Case 2 (patient 8) was a 24-year-old man who was referred to an intensive care unit (ICU) for NORSE. The NORSE continued for 2 months, even after treatments with multiple antiepileptic drugs (AEDs) and anesthetics.
After receiving tofacitinib 5 mg twice daily, 4 months after the disease onset, the patient had improved rhythmic burst shown by EEG by as early as day 10. Additionally, they showed a small amount of theta to delta waves with no definite epileptiform discharge on day 16, without any additional immunotherapy AEDs.
"Further analysis is required to find the optimal candidate for disease and duration of treatment for the use of tofacitinib in autoimmune encephalitis,” Jang et al wrote.
